Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTVT8PLU)

• DOT Name: Metallothionein-1M (MT1M)
• Synonyms: MT-1M; Metallothionein-IM; MT-IM
• Gene Name: MT1M
• Related Disease:
  Advanced cancer
  Amyotrophic lateral sclerosis type 1
  Androgen insensitivity syndrome
  Breast carcinoma
  Classic Hodgkin lymphoma
  Colonic neoplasm
  Creutzfeldt Jacob disease
  Glioma
  Graves disease
  Huntington disease
  Laryngeal carcinoma
  Laryngeal squamous cell carcinoma
  Lymphosarcoma
  Malignant pleural mesothelioma
  Nephritis
  Thyroid cancer
  Thyroid gland carcinoma
  Thyroid gland papillary carcinoma
  Thyroid tumor
  Lung cancer
  Lung carcinoma
  Pancreatic cancer
  Non-small-cell lung cancer
  Breast cancer
  Breast neoplasm
  Clear cell renal carcinoma
  Glaucoma/ocular hypertension
  Lupus nephritis
  Non-insulin dependent diabetes
  Prostate cancer
  Prostate carcinoma
  Renal cell carcinoma
  Squamous cell carcinoma
  Stroke
  Systemic lupus erythematosus
  Thyroid gland follicular carcinoma
• UniProt ID: MT1M_HUMAN
• Pfam ID: PF00131
• Sequence:
  MDPNCSCTTGVSCACTGSCTCKECKCTSCKKSCCSCCPVGCAKCAHGCVCKGTLENCSCC
  A
• Function: Metallothioneins have a high content of cysteine residues that bind various heavy metals; these proteins are transcriptionally regulated by both heavy metals and glucocorticoids.
• KEGG Pathway: Mineral absorption (hsa04978)
• Reactome Pathway: Metallothioneins bind metals (R-HSA-5661231)

Molecular Interaction Atlas (MIA) of This DOT

36 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Advanced cancer	DISAT1Z9	Strong	Biomarker	[1]
Amyotrophic lateral sclerosis type 1	DIS5A2M0	Strong	Biomarker	[2]
Androgen insensitivity syndrome	DISUZBBO	Strong	Altered Expression	[3]
Breast carcinoma	DIS2UE88	Strong	Biomarker	[4]
Classic Hodgkin lymphoma	DISV1LU6	Strong	Genetic Variation	[5]
Colonic neoplasm	DISSZ04P	Strong	Posttranslational Modification	[6]
Creutzfeldt Jacob disease	DISCB6RX	Strong	Biomarker	[7]
Glioma	DIS5RPEH	Strong	Biomarker	[8]
Graves disease	DISU4KOQ	Strong	Biomarker	[9]
Huntington disease	DISQPLA4	Strong	Altered Expression	[10]
Laryngeal carcinoma	DISNHCIV	Strong	Biomarker	[11]
Laryngeal squamous cell carcinoma	DIS9UUVF	Strong	Biomarker	[11]
Lymphosarcoma	DISGYV3F	Strong	Posttranslational Modification	[12]
Malignant pleural mesothelioma	DIST2R60	Strong	Biomarker	[1]
Nephritis	DISQZQ70	Strong	Altered Expression	[13]
Thyroid cancer	DIS3VLDH	Strong	Altered Expression	[14]
Thyroid gland carcinoma	DISMNGZ0	Strong	Altered Expression	[14]
Thyroid gland papillary carcinoma	DIS48YMM	Strong	Biomarker	[14]
Thyroid tumor	DISLVKMD	Strong	Altered Expression	[14]
Lung cancer	DISCM4YA	moderate	Genetic Variation	[15]
Lung carcinoma	DISTR26C	moderate	Genetic Variation	[15]
Pancreatic cancer	DISJC981	moderate	Altered Expression	[16]
Non-small-cell lung cancer	DIS5Y6R9	Disputed	Altered Expression	[17]
Breast cancer	DIS7DPX1	Limited	Biomarker	[4]
Breast neoplasm	DISNGJLM	Limited	Altered Expression	[18]
Clear cell renal carcinoma	DISBXRFJ	Limited	Posttranslational Modification	[19]
Glaucoma/ocular hypertension	DISLBXBY	Limited	Genetic Variation	[20]
Lupus nephritis	DISCVGPZ	Limited	Altered Expression	[13]
Non-insulin dependent diabetes	DISK1O5Z	Limited	Altered Expression	[21]
Prostate cancer	DISF190Y	Limited	Altered Expression	[22]
Prostate carcinoma	DISMJPLE	Limited	Altered Expression	[22]
Renal cell carcinoma	DISQZ2X8	Limited	Posttranslational Modification	[19]
Squamous cell carcinoma	DISQVIFL	Limited	Posttranslational Modification	[23]
Stroke	DISX6UHX	Limited	Biomarker	[24]
Systemic lupus erythematosus	DISI1SZ7	Limited	Altered Expression	[13]
Thyroid gland follicular carcinoma	DISFK2QT	Limited	Altered Expression	[25]

2 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate increases the methylation of Metallothionein-1M (MT1M).	[26]
Arsenic	DMTL2Y1	Approved	Arsenic affects the methylation of Metallothionein-1M (MT1M).	[30]

22 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Ciclosporin	DMAZJFX	Approved	Ciclosporin increases the expression of Metallothionein-1M (MT1M).	[27]
Acetaminophen	DMUIE76	Approved	Acetaminophen increases the expression of Metallothionein-1M (MT1M).	[28]
Cupric Sulfate	DMP0NFQ	Approved	Cupric Sulfate decreases the expression of Metallothionein-1M (MT1M).	[29]
Estradiol	DMUNTE3	Approved	Estradiol increases the expression of Metallothionein-1M (MT1M).	[27]
Quercetin	DM3NC4M	Approved	Quercetin increases the expression of Metallothionein-1M (MT1M).	[31]
Arsenic trioxide	DM61TA4	Approved	Arsenic trioxide increases the expression of Metallothionein-1M (MT1M).	[32]
Decitabine	DMQL8XJ	Approved	Decitabine increases the expression of Metallothionein-1M (MT1M).	[33]
Progesterone	DMUY35B	Approved	Progesterone increases the expression of Metallothionein-1M (MT1M).	[34]
Fluorouracil	DMUM7HZ	Approved	Fluorouracil increases the expression of Metallothionein-1M (MT1M).	[35]
Dexamethasone	DMMWZET	Approved	Dexamethasone increases the expression of Metallothionein-1M (MT1M).	[36]
Cannabidiol	DM0659E	Approved	Cannabidiol increases the expression of Metallothionein-1M (MT1M).	[37]
Malathion	DMXZ84M	Approved	Malathion increases the expression of Metallothionein-1M (MT1M).	[38]
Deoxycholic acid	DM3GYAL	Approved	Deoxycholic acid increases the expression of Metallothionein-1M (MT1M).	[39]
Phenoxybenzamine	DM8KSQH	Approved	Phenoxybenzamine increases the expression of Metallothionein-1M (MT1M).	[39]
Amiodarone	DMUTEX3	Phase 2/3 Trial	Amiodarone increases the expression of Metallothionein-1M (MT1M).	[40]
Disulfiram	DMCL2OK	Phase 2 Trial	Disulfiram increases the expression of Metallothionein-1M (MT1M).	[39]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene decreases the expression of Metallothionein-1M (MT1M).	[41]
Leflunomide	DMR8ONJ	Phase 1 Trial	Leflunomide increases the expression of Metallothionein-1M (MT1M).	[42]
Clioquinol	DM746BZ	Withdrawn from market	Clioquinol increases the expression of Metallothionein-1M (MT1M).	[39]
Astemizole	DM2HN6Q	Withdrawn from market	Astemizole increases the expression of Metallothionein-1M (MT1M).	[39]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A affects the expression of Metallothionein-1M (MT1M).	[43]
Lead acetate	DML0GZ2	Investigative	Lead acetate increases the expression of Metallothionein-1M (MT1M).	[44]

References

• [1] Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.Oncotarget. 2018 Apr 27;9(32):22254-22268. doi: 10.18632/oncotarget.24962. eCollection 2018 Apr 27.
• [2] Reduction of metallothioneins promotes the disease expression of familial amyotrophic lateral sclerosis mice in a dose-dependent manner.Eur J Neurosci. 2001 Apr;13(7):1363-70. doi: 10.1046/j.0953-816x.2001.01512.x.
• [3] Abnormal melatonin receptor 1B expression in osteoblasts from girls with adolescent idiopathic scoliosis.J Pineal Res. 2011 May;50(4):395-402. doi: 10.1111/j.1600-079X.2011.00857.x. Epub 2011 Feb 24.
• [4] A case-control study of Metallothionein-1 expression in breast cancer and breast fibroadenoma.Sci Rep. 2019 May 15;9(1):7407. doi: 10.1038/s41598-019-43565-0.
• [5] A novel MspI PCR-RFLP in the human cytosine 5-methyltransferase gene: lack of relevance for malignant lymphoproliferative disease and breast cancer.Hum Hered. 1998 Jul-Aug;48(4):226-9. doi: 10.1159/000022805.
• [6] Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line.Proc Natl Acad Sci U S A. 1992 May 15;89(10):4495-9. doi: 10.1073/pnas.89.10.4495.
• [7] Differential expression of metallothioneins in human prion diseases.Dement Geriatr Cogn Disord. 2000 Sep-Oct;11(5):251-62. doi: 10.1159/000017247.
• [8] The melatonin-MT1 receptor axis modulates tumor growth in PTEN-mutated gliomas.Biochem Biophys Res Commun. 2018 Feb 19;496(4):1322-1330. doi: 10.1016/j.bbrc.2018.02.010.
• [9] Expression of Metallothionein I/II and Ki-67 Antigen in Graves' Disease.Anticancer Res. 2018 Dec;38(12):6847-6853. doi: 10.21873/anticanres.13059.
• [10] The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity.J Neurosci. 2011 Oct 12;31(41):14496-507. doi: 10.1523/JNEUROSCI.3059-11.2011.
• [11] Potential biomarkers for head and neck squamous cell carcinoma.Laryngoscope. 2003 Mar;113(3):393-400. doi: 10.1097/00005537-200303000-00001.
• [12] Physical and functional interaction of DNA methyltransferase 3A with Mbd3 and Brg1 in mouse lymphosarcoma cells.Cancer Res. 2005 Dec 1;65(23):10891-900. doi: 10.1158/0008-5472.CAN-05-1455.
• [13] The renal metallothionein expression profile is altered in human lupus nephritis.Arthritis Res Ther. 2008;10(4):R76. doi: 10.1186/ar2450. Epub 2008 Jul 6.
• [14] Low metallothionein 1M (MT1M) is associated with thyroid cancer cell lines progression.Am J Transl Res. 2019 Mar 15;11(3):1760-1770. eCollection 2019.
• [15] Impact of metallothionein gene polymorphisms on the risk of lung cancer in a Japanese population.Mol Carcinog. 2015 Jun;54 Suppl 1:E122-8. doi: 10.1002/mc.22198. Epub 2014 Aug 30.
• [16] Orchestrating a biomarker panel with lncRNAs and mRNAs for predicting survival in pancreatic ductal adenocarcinoma.J Cell Biochem. 2018 Sep;119(9):7696-7706. doi: 10.1002/jcb.27119. Epub 2018 Jun 20.
• [17] Metallothionein 1F and 2A overexpression predicts poor outcome of non-small cell lung cancer patients.Exp Mol Pathol. 2013 Feb;94(1):301-8. doi: 10.1016/j.yexmp.2012.10.006. Epub 2012 Oct 9.
• [18] Immunohistochemical Expression of Melatonin Receptor MT1 and Glucose Transporter GLUT1 in Human Breast Cancer.Anticancer Agents Med Chem. 2018;18(15):2110-2116. doi: 10.2174/1871520618666181025125532.
• [19] DNA methylation of metallothionein genes is associated with the clinical features of renal cell carcinoma.Oncol Rep. 2019 Jun;41(6):3535-3544. doi: 10.3892/or.2019.7109. Epub 2019 Apr 10.
• [20] Variations in the myocilin gene in patients with open-angle glaucoma.Arch Ophthalmol. 2002 Sep;120(9):1189-97. doi: 10.1001/archopht.120.9.1189.
• [21] Metallothionein-mediated antioxidant defense system and its response to exercise training are impaired in human type 2 diabetes.Diabetes. 2005 Nov;54(11):3089-94. doi: 10.2337/diabetes.54.11.3089.
• [22] Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-B): potential implications on prostate cancer chemoprevention and therapy.J Pineal Res. 2013 Jan;54(1):69-79. doi: 10.1111/j.1600-079X.2012.01026.x. Epub 2012 Aug 1.
• [23] A low DNA methylation epigenotype in lung squamous cell carcinoma and its association with idiopathic pulmonary fibrosis and poorer prognosis.Int J Cancer. 2020 Jan 15;146(2):388-399. doi: 10.1002/ijc.32532. Epub 2019 Jul 8.
• [24] Metallothionein I as a direct link between therapeutic hematopoietic stem/progenitor cells and cerebral protection in stroke.FASEB J. 2018 May;32(5):2381-2394. doi: 10.1096/fj.201700746R. Epub 2017 Dec 21.
• [25] A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples.Mod Pathol. 2007 Oct;20(10):1095-102. doi: 10.1038/modpathol.3800943. Epub 2007 Jul 27.
• [26] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [27] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [28] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [29] Extremely low copper concentrations affect gene expression profiles of human prostate epithelial cell lines. Chem Biol Interact. 2010 Oct 6;188(1):214-9.
• [30] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [31] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [32] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [33] Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.
• [34] Progesterone regulation of implantation-related genes: new insights into the role of oestrogen. Cell Mol Life Sci. 2007 Apr;64(7-8):1009-32.
• [35] Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer. 2004 Nov 1;112(2):200-12. doi: 10.1002/ijc.20401.
• [36] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [37] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [38] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [39] Identification of novel activators of the metal responsive transcription factor (MTF-1) using a gene expression biomarker in a microarray compendium. Metallomics. 2020 Sep 23;12(9):1400-1415. doi: 10.1039/d0mt00071j.
• [40] Capturing time-dependent activation of genes and stress-response pathways using transcriptomics in iPSC-derived renal proximal tubule cells. Cell Biol Toxicol. 2023 Aug;39(4):1773-1793. doi: 10.1007/s10565-022-09783-5. Epub 2022 Dec 31.
• [41] Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
• [42] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [43] Comprehensive analysis of transcriptomic changes induced by low and high doses of bisphenol A in HepG2 spheroids in vitro and rat liver in vivo. Environ Res. 2019 Jun;173:124-134. doi: 10.1016/j.envres.2019.03.035. Epub 2019 Mar 18.
• [44] Analysis of lead toxicity in human cells. BMC Genomics. 2012 Jul 27;13:344.